[PDF][PDF] Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and …
C Denkert, G Von Minckwitz, JC Brase, BV Sinn… - J Clin oncol, 2015 - academia.edu
J Clin oncol, 2015•academia.edu
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic
strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2
(HER2)–positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-
infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant
GeparSixto trial.
strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2
(HER2)–positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-
infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant
GeparSixto trial.
Purpose
Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2)–positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial.
academia.edu